QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=C1188DFB6C25D0C9A6AAC30CD302840A;jsessionid=4FD711A71D7C22919E2D55A0F42BB902;jsessionid=318464DC06246D1973A91591DA97A77C;jsessionid=719C845EE021091DFC53926374D0FFBF;jsessionid=3F3EB08AB742C7EB7A0AC70CBE1355E3 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=C1188DFB6C25D0C9A6AAC30CD302840A;jsessionid=4FD711A71D7C22919E2D55A0F42BB902;jsessionid=318464DC06246D1973A91591DA97A77C;jsessionid=719C845EE021091DFC53926374D0FFBF;jsessionid=3F3EB08AB742C7EB7A0AC70CBE1355E3